Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2018
Lead Product(s) : AQX-1125
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2018
Lead Product(s) : AQX-1125
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AQX-1125
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2017
Lead Product(s) : AQX-1125
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2016
Lead Product(s) : AQX-1125
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Innovaderm
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 24, 2014
Lead Product(s) : AQX-1125
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Innovaderm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AQX-1125
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of AQX-1125 in Unstable COPD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2013
Lead Product(s) : AQX-1125
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of AQX-1125 in IC/BPS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2013
Reset All
